RBC Capital on Ideaya Biosciences (IDYA): 'R&D Day Underscores Strengths & Expansive Pipeline'
Tweet Send to a Friend
RBC Capital analyst Gregory Renza reiterated an Outperform rating and $61.00 price target on Ideaya Biosciences (NASDAQ: IDYA).The analyst said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
